glp 1 babies So-Called “Ozempic Babies” Raise Questions About Unintended Effects of GLP-1 Agonists Ozempic's baby boom: Docs discuss
Description
Congratulations to Eli Lilly and the broader obesity treatment community
GLP-1 receptor agonists emerged from diabetes research and now represent a major advancement in weight management
With the weight-loss drug market surpassing $100 billion, legal and regulatory risks are intensifying
Recent data also strongly associate maternal postprandial hypoglycemia with adverse fetal outcomes, specifically a nearly two-fold increased risk of delivering a small-for-gestational-age (SGA) infant and higher rates of low birth weight
Understand the impact of GLP-1 medications on mental health and how they can affect your mood.
Learn the risks of grey market tirzepatide, from contamination to dosing errors
